PEA for Chemotherapy-Induced Neuropathy
Author Information
Author(s): Davis Mellar P., Ulrich Angela, Segal Rebecca, Gudena Vinay, Ruddy Kathryn J., D’Andre Stacy, Giridhar Karthik V., Vasireddy Vamsi K., Agarwal Rajiv, Azzouqa Abdel-Ghani, Novotny Paul, McCue Shaylene, Bauer Brent, Loprinzi Charles L., Liedtke Wolfgang
Primary Institution: Mayo Clinic
Hypothesis
Does palmitoylethanolamide (PEA) improve symptoms of established chemotherapy-induced peripheral neuropathy (CIPN)?
Conclusion
PEA failed to improve established chemotherapy-induced neuropathy.
Supporting Evidence
- PEA did not show any significant improvement compared to placebo in treating established CIPN.
- Quality of life measures were similar across all treatment arms.
- 85% of participants completed the 8-week treatment period.
Takeaway
This study tested a substance called PEA to see if it could help people with nerve pain from chemotherapy, but it didn't work.
Methodology
A double-blind, placebo-controlled, randomized trial comparing PEA to placebo in patients with established CIPN.
Limitations
The study only included patients with established CIPN and did not assess PEA's effectiveness in preventing CIPN.
Participant Demographics
{"total":89,"gender":{"male":17,"female":71},"age":{"median":63.5}}
Statistical Information
P-Value
0.11
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website